• To provide access to melphalan/HDS for patients with hepatic-dominant metastatic ocular melanoma
• To evaluate the safety of treatment with melphalan/HDS

Key Inclusion Criteria

• 50% or less ocular melanoma metastases in the liver
• Liver disease must be measurable by CT and/or MRI
• Evidence of limited extrahepatic disease at baseline is acceptable if the life-threatening component of progressive disease is in the liver
• ECOG PS of 0-1 at screening
• Prior chemotherapy, radiotherapy, chemoembolization, radioembolization, or immunoembolization is allowed with a washout period
• Patients receiving anti–PD-1 immunotherapy such as pembrolizumab or nivolumab, or anti–CTLA-4 immunotherapy such as ipilimumab should wait 8 weeks before receiving PHP treatment

Key Exclusion Criteria

• Patients with notable cirrhosis or with evidence of portal hypertension
• Cardiac conditions preventing the use of general anesthesia
• Clinically significant pulmonary disease that prevents the use of general anesthesia
• Patients taking immunosuppressive drugs or who are unable to be temporarily removed from chronic anticoagulation therapy
• Patients with active bacterial infections with systemic manifestations (malaise, fever, leukocytosis) are not eligible until completion of appropriate therapy